Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
08:23am, Tuesday, 21'st Oct 2025
>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances. Plan
West Pharmaceutical Services: HVP Moat Cum GLP-1 And Biologics Tailwinds Reinforce Upward Momentum
05:57am, Tuesday, 21'st Oct 2025
West Pharmaceutical Services earns a Buy rating with a $320 price target, reflecting ~18% upside with strong long-term growth prospects. WST's high-value product mix is expanding, driving margin growt
- The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of s mall
Abbott: GLP-1 Beneficiary - A Dividend Raise May Be Coming
09:39am, Saturday, 18'th Oct 2025
The market has overreacted to ABT's lowered FY2025 organic sales growth/narrowed adj. EPS, since the management continues to deliver robust numbers while building upon FY2024 outperformance. Much of i
President Trump targets $150 MFN price for GLP-1s
07:32pm, Friday, 17'th Oct 2025
Shares of Eli Lilly and Novo Nordisk came under pressure after President Trump said during an event at the White House that the administration is looking bring down prices of popular weight loss GLP-1
Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
05:25pm, Friday, 17'th Oct 2025
Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of th
Is Trump Going to Kill the GLP-1 Cash Cow?
11:05am, Friday, 17'th Oct 2025
GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but Pres
WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage
09:10am, Friday, 17'th Oct 2025
Provides a Differentiated Cost-Sharing Framework for GLP-1 Medications Paired With Clinical Oversight and Proven Behavior Change Support from WeightWatchers Clinic Provides a Differentiated Cost-Shari
Lilly's oral GLP-1 drug helps reduce blood sugar levels in late-stage trials
06:51am, Wednesday, 15'th Oct 2025
Eli Lilly said on Wednesday its oral drug, orforglipron, helped reduce blood sugar levels in two late-stage trials.
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with ins
Global Partners Announces Cash Distribution on Series B Preferred Units
08:30am, Tuesday, 14'th Oct 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declare
Global Partners: A Midstream Underdog Ready For The Next Energy Upcycle
06:47am, Tuesday, 14'th Oct 2025
Global Partners LP is a leading midstream and retail energy MLP with strong cash flows and a robust, vertically integrated business model. GLP's recent acquisitions and disciplined capital management
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, which supports once-monthly subcutaneous (SQ) dosing i
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
07:00am, Tuesday, 07'th Oct 2025
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the po
Novo Nordisk: Oral Wegovy Nears FDA Decision As GLP-1 Momentum Builds
06:14am, Tuesday, 07'th Oct 2025
Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill. NVO's first-half 2025 results showed robust growth, driven by obesity fran
